Protagenic Therapeutics Stock Performance
| PTIX Stock | USD 0.40 0.09 18.37% |
The company holds a Beta of -2.89, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Protagenic Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Protagenic Therapeutics is expected to outperform it. At this point, Protagenic Therapeutics has a negative expected return of -1.88%. Please make sure to check Protagenic Therapeutics' total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Protagenic Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Protagenic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:14 | Dividend Date 2016-07-27 | Last Split Date 2025-05-05 |
1 | Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 11/13/2025 |
2 | Can Protagenic Therapeutics Inc. stock hit consensus price targets - July 2025 Breakouts Weekly High Return Opportunities - newser.com | 11/19/2025 |
3 | Acquisition by Wright Timothy R of 21250 shares of Protagenic Therapeutics at 1.74 subject to Rule 16b-3 | 11/21/2025 |
4 | What analysts say about Protagenic Therapeutics Inc stock - Stock Buyback Announcements Free Discover Massive Upside Stocks - earlytimes.in | 11/24/2025 |
5 | Results from Phase 1 Multiple-Dose Study of PT00114 | 12/09/2025 |
6 | After Leaping 26 percent Performance Technologies S.A. Shares Are Not Flying Under The Radar | 01/09/2026 |
7 | Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal Retail Turns Extremely Bullish - MSN | 01/26/2026 |
8 | Is Modine Quietly Recasting Its Moat Around Data Center Climate Solutions | 02/04/2026 |
| Begin Period Cash Flow | 1.3 M | |
| Total Cashflows From Investing Activities | 2.8 M |
Protagenic | Build AI portfolio with Protagenic Stock |
Protagenic Therapeutics Relative Risk vs. Return Landscape
If you would invest 189.00 in Protagenic Therapeutics on November 9, 2025 and sell it today you would lose (149.00) from holding Protagenic Therapeutics or give up 78.84% of portfolio value over 90 days. Protagenic Therapeutics is currently does not generate positive expected returns and assumes 10.9296% risk (volatility on return distribution) over the 90 days horizon. In different words, 98% of stocks are less volatile than Protagenic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagenic Therapeutics Target Price Odds to finish over Current Price
The tendency of Protagenic Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.40 | 90 days | 0.40 | about 91.66 |
Based on a normal probability distribution, the odds of Protagenic Therapeutics to move above the current price in 90 days from now is about 91.66 (This Protagenic Therapeutics probability density function shows the probability of Protagenic Stock to fall within a particular range of prices over 90 days) .
Protagenic Therapeutics Price Density |
| Price |
Predictive Modules for Protagenic Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protagenic Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protagenic Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Protagenic Therapeutics is not an exception. The market had few large corrections towards the Protagenic Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protagenic Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protagenic Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.96 | |
β | Beta against Dow Jones | -2.89 | |
σ | Overall volatility | 0.68 | |
Ir | Information ratio | -0.21 |
Protagenic Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protagenic Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protagenic Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protagenic Therapeutics generated a negative expected return over the last 90 days | |
| Protagenic Therapeutics has high historical volatility and very poor performance | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (4.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from simplywall.st: Is Modine Quietly Recasting Its Moat Around Data Center Climate Solutions |
Protagenic Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protagenic Stock often depends not only on the future outlook of the current and potential Protagenic Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protagenic Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.9 M | |
| Cash And Short Term Investments | 1.8 M |
Protagenic Therapeutics Fundamentals Growth
Protagenic Stock prices reflect investors' perceptions of the future prospects and financial health of Protagenic Therapeutics, and Protagenic Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagenic Stock performance.
| Return On Equity | -5.13 | ||||
| Return On Asset | -1.9 | ||||
| Current Valuation | 2.22 M | ||||
| Shares Outstanding | 1.93 M | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 1.61 X | ||||
| EBITDA | (5.47 M) | ||||
| Net Income | (5.53 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 942.76 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | (2.43) X | ||||
| Cash Flow From Operations | (4.22 M) | ||||
| Earnings Per Share | (13.13) X | ||||
| Market Capitalization | 776.94 K | ||||
| Total Asset | 1.96 M | ||||
| Retained Earnings | (36.3 M) | ||||
| Working Capital | 940.11 K | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
About Protagenic Therapeutics Performance
Evaluating Protagenic Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protagenic Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protagenic Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 269.53 | 277.63 | |
| Return On Tangible Assets | (3.25) | (3.09) | |
| Return On Capital Employed | (6.47) | (6.15) | |
| Return On Assets | (3.25) | (3.09) | |
| Return On Equity | (4.91) | (4.66) |
Things to note about Protagenic Therapeutics performance evaluation
Checking the ongoing alerts about Protagenic Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagenic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagenic Therapeutics generated a negative expected return over the last 90 days | |
| Protagenic Therapeutics has high historical volatility and very poor performance | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (4.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from simplywall.st: Is Modine Quietly Recasting Its Moat Around Data Center Climate Solutions |
- Analyzing Protagenic Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagenic Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagenic Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagenic Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagenic Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagenic Therapeutics' stock. These opinions can provide insight into Protagenic Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.